A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Sikander Ailawadhi, Kevin R. Kelly, Robert A. Vescio, Sundar Jagannath, Jeffrey Wolf, Mecide Gharibo, Taimur Sher, Leyla Bojanini, Maurice Kirby, Asher Chanan-Khan

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences